Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B.
Rijckborst V, ter Borg MJ, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, Simon K, Raptopoulou-Gigi M, Ormeci N, Zondervan PE, Verhey E, van Vuuren AJ, Hansen BE, Janssen HL; PARC Study Group. Rijckborst V, et al. Am J Gastroenterol. 2010 Aug;105(8):1762-9. doi: 10.1038/ajg.2010.186. Epub 2010 May 11. Am J Gastroenterol. 2010. PMID: 20461068 Clinical Trial.
Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon α-2a: progressive decrease in hepatitis B surface antigen in responders.
Rijckborst V, Ferenci P, Akdogan M, Pinarbasi B, ter Borg MJ, Simon K, Flisiak R, Akarca US, Raptopoulou-Gigi M, Verhey E, van Vuuren AJ, Boucher CA, Hansen BE, Janssen HL; PARC Study Group. Rijckborst V, et al. Among authors: raptopoulou gigi m. Eur J Gastroenterol Hepatol. 2012 Sep;24(9):1012-9. doi: 10.1097/MEG.0b013e3283557e23. Eur J Gastroenterol Hepatol. 2012. PMID: 22668876 Clinical Trial.
Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort.
Papatheodoridis GV, Manolakopoulos S, Touloumi G, Nikolopoulou G, Raptopoulou-Gigi M, Gogos C, Vafiadis-Zouboulis I, Karamanolis D, Chouta A, Ilias A, Drakoulis C, Mimidis K, Ketikoglou I, Manesis E, Mela M, Hatzis G, Dalekos GN; HepNet.Greece Study Group. Papatheodoridis GV, et al. Among authors: raptopoulou gigi m. J Viral Hepat. 2015 Feb;22(2):120-7. doi: 10.1111/jvh.12283. Epub 2014 Jul 15. J Viral Hepat. 2015. PMID: 25040685
Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
Papatheodoridis GV, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou-Gigi M, Vafiadis-Zoumbouli I, Vasiliadis T, Mimidis K, Gogos C, Ketikoglou I, Manesis EK; HEPNET. Greece Cohort Study Group. Papatheodoridis GV, et al. Among authors: raptopoulou gigi m. Gut. 2011 Aug;60(8):1109-16. doi: 10.1136/gut.2010.221846. Epub 2011 Jan 26. Gut. 2011. PMID: 21270118 Clinical Trial.
Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.
Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, Peng CY, Myers RP, Brown RS Jr, Jeffers L, Tsai N, Bialkowska J, Tang S, Beebe S, Cooney E. Liaw YF, et al. Among authors: raptopoulou gigi m. Hepatology. 2011 Jul;54(1):91-100. doi: 10.1002/hep.24361. Hepatology. 2011. PMID: 21503940 Clinical Trial.
40 results